Episode 40
Biotech Hangout
00:00
Is There a Cure for Alzheimer's?
I think the data pretty much held up. You know, there are a few smallish red flags, but on the whole, this is a, you know, I think ASI ran a very robust study and they asked the right questions and they basically aced all the important endpoints. The question is, will it also be approved in APEV4 on the zygotes, given that they had the high incidence of area E? We won't know that until next year, middle of next year, that's the next big catalyst for Denamab. It looks stronger on a cross-trial basis than any of the other AB-to antibodies. And obviously, the big caveat
Transcript
Play full episode
